These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22001083)

  • 1. Primary, secondary, and tertiary prevention of cardiovascular disease in patients with HIV disease: a guide for nurse practitioners.
    Jones-Parker H
    J Assoc Nurses AIDS Care; 2012; 23(2):124-33. PubMed ID: 22001083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV infection, aging and cardiovascular disease: epidemiology and prevention.
    Petoumenos K; Worm SW
    Sex Health; 2011 Dec; 8(4):465-73. PubMed ID: 22127031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease and HIV infection: host, virus, or drugs?
    Martínez E; Larrousse M; Gatell JM
    Curr Opin Infect Dis; 2009 Feb; 22(1):28-34. PubMed ID: 19532078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
    Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular disease in HIV-infected patients.
    Das S
    J Antimicrob Chemother; 2010 Mar; 65(3):386-9. PubMed ID: 20026610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
    Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M;
    Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment.
    Steinhart CR; Emons MF
    AIDS Read; 2004 Feb; 14(2):86-90, 93-5. PubMed ID: 14997864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.
    Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R
    Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heart of the matter: reducing CVD risk.
    Hayman LL; Kamau MW; Stuart-Shor EM
    Nurse Pract; 2009 May; 34(5):30-5. PubMed ID: 19390396
    [No Abstract]   [Full Text] [Related]  

  • 18. [Increased cardiovascular risk in HIV patients].
    Wierema TK
    Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
    Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
    HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.